The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer (Q35582540)

9 August 2017

title

The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer (English)

1 reference

9 August 2017

1 reference

Lorelei A Mucci

1 reference

9 August 2017

Massimo Loda

1 reference

9 August 2017

Edward L. Giovannucci

object named as

Edward L Giovannucci

1 reference

9 August 2017

Bernard Rosner

1 reference

9 August 2017

Rebecca E Graff

1 reference

9 August 2017

Andreas Pettersson

1 reference

9 August 2017

Rosina T Lis

1 reference

9 August 2017

Natalie DuPre

1 reference

9 August 2017

Kristina M Jordahl

1 reference

9 August 2017

Elizabeth Nuttall

1 reference

9 August 2017

Jennifer R Rider

1 reference

9 August 2017

Michelangelo Fiorentino

1 reference

9 August 2017

Howard D Sesso

1 reference

9 August 2017

Stacey A Kenfield

1 reference

9 August 2017

Paul L Nguyen

1 reference

9 August 2017

Christopher J Sweeney

1 reference

9 August 2017

Transdisciplinary Prostate Cancer Partnership ToPCaP

1 reference

9 August 2017

publication date

1 March 2015

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

897-906

1 reference

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Antibody-based detection of ERG rearrangement-positive prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

ETS gene fusions in prostate cancer: from discovery to daily clinical practice

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

ETS transcription factors and their emerging roles in human cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

A randomized trial of aspirin and beta-carotene among U.S. physicians

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

The Ability of Biomarkers to Predict Systemic Progression in Men with High-Risk Prostate Cancer Treated Surgically Is Dependent on ERG Status

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4424159

Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity

26 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FPROS.22973

Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25728532

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25728532

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1002/PROS.22973

1 reference

9 August 2017

1 reference

9 August 2017

1 reference